ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ANAB / dividends
GHRS (49) TYRA (30) PCRX (65) KRSA (38) ⌘ Pro Terminal →

AnaptysBio Inc. (ANAB) Dividend Safety Gauge & 10-Year DRIP Compounder

$46.91 -2.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $46.58

AnaptysBio Inc. (ANAB) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.43B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, AnaptysBio Inc. (NASDAQ: ANAB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $46.91 (-2.84% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, ANAB ranks #163 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANAB compare to GHRS and TYRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANAB carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, GHRS (GH Research PLC) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.43B) and TYRA (Tyra Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B). Among the 5-stock peer group, ANAB leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANAB?
▼

Per ANAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001370053), AnaptysBio Inc. generated $234.6M in revenue (+157.0% YoY), -$13.2M in net income, and $19.6M in free cash flow against $364.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $46.58 (-0.70%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 8.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510060
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C · Rk D+
Cash (19)Whales (8)SEC (13)Macro (10)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE+0.9% Base Target
$76 Bull$47 Base$37 Bear
📬 FREE ANAB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANAB)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (60/100 Composite)
🔍 WHY ANAB SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (32% of score)

SEC XBRL FY 2025 (10-K): 8.4% FCF Margin ($19.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$45.59-0.4% Next Q
Q2 (-2Q)
55
Grade C$45.43+9.2% Next Q
Q3 (-1Q)
57
Grade C$49.63-5.5% Next Q
Current
60
Grade C-$46.91+0.4% Hist 90D α
Trajectory: C- (52) → C- (60)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ANAB Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, ANAB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($51.37) or 200D SMA ($50.58) invalidates the momentum regime and cuts Target Base ($47.33) toward Bear Floor ($36.92).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 60%NO 40%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr
$11.5K
Yr 1
$13.2K
Yr 2
$15.2K
Yr 3
$17.6K
Yr 4
$20.2K
Yr 5
$23.3K
Yr 6
$26.8K
Yr 7
$30.8K
Yr 8
$35.5K
Yr 9
$40.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in ANAB & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on ANAB and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ANAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.77%▼ DESCENDING CHANNEL
2026-11-03O $48.64H $48.64L $46.91C $46.91VOL 293.6K
RES: $49.88SUP: $43.13SMA50: $51.37SMA200: $50.58
$75.39$62.84$50.28$37.73$25.17RES $49.88SUP $43.13$46.912026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANAB Butterfly Map → + Track ANAB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-7.6%/yr Implied 5Y Growth

vs. +157.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANAB)

Health Care Rank #163 of 1015 ⚔️ GHRS vs ANAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANAB vs. GHRS, TYRA, PCRX, KRSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AnaptysBio Inc. (ANAB) ranks #163 by composite RQD confidence (60/100, grade C-) and #307 by equity capitalization ($1.43B). Within this direct 5-issuer industry benchmark cohort, ANAB leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PCRX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ANAB at 60/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANAB ACTIVE
AnaptysBio Inc.
C- 60/100 — — 85.0% -2.84% $1.43B Benchmark Subject
GHRS
GH Research PLC
D 49/100 — — — -1.73% $1.43B /ghrs-vs-anab →
TYRA
Tyra Biosciences Inc.
E 30/100 — — -35.0% +1.23% $1.45B /tyra-vs-anab →
PCRX
Pacira BioSciences Inc.
C 65/100 — 79.4% 1.7% +0.03% $1.45B /pcrx-vs-anab →
KRSA
Korsana Biosciences Inc.
D- 38/100 — — -5.7% +5.04% $1.37B /krsa-vs-anab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001370053 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AnaptysBio Inc. (ANAB) reported GAAP revenue of $234.6M (+157.0% vs. FY2024 revenue of $91.3M , and +1267.4% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of $19.7M, and free cash flow of $19.6M (+114.5% YoY). On the balance sheet, ANAB closed FY2025 with $364.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $234.6M -$13.2M $19.7M $19.6M $364.4M —
FY2024 (FY) 2024-12-31 $91.3M -$145.2M -$135.3M -$135.7M $483.8M —
FY2023 (FY) 2023-12-31 $17.2M -$163.6M -$120.8M -$120.8M — —

3. ANAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AnaptysBio Inc. (NASDAQ: ANAB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $46.91 (-2.84% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, ANAB ranks #163 in composite RQD confidence.

How does ANAB compare to GHRS and TYRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANAB carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, GHRS (GH Research PLC) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.43B) and TYRA (Tyra Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B). Among the 5-stock peer group, ANAB leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANAB?

Per ANAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001370053), AnaptysBio Inc. generated $234.6M in revenue (+157.0% YoY), -$13.2M in net income, and $19.6M in free cash flow against $364.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ANAB last traded at $46.91 (-2.84% on volume of 281,503 shares), positioning the stock -8.68% below its 50-day simple moving average ($51.37) and -7.26% below its 200-day simple moving average ($50.58). Across its 52-week range of $20.18 to $72.36, ANAB sits at the 51.2% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($42.55 to $51.27).

Direct Sub-Reports: ANAB RQD Cockpit ANAB 12M Forecast ANAB Earnings & Move ANAB Dividends & DRIP ANAB Insiders & 13F ANAB Whale Options ANAB Profit Sankey ANAB News & Why
ROARABLE RATING BRIEF • RQD 60/100 (C-) ✓ SEC XBRL & RQD VERIFIED

ANAB — AnaptysBio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AnaptysBio Inc. (ANAB) earns a live Roarable RQD composite score of 60/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $46.91 (-2.84% 1D, market capitalization $1.43B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of —, operating margin of 75.0%, and free cash flow yield of 1.36%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AnaptysBio Inc. (ANAB) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $1.43B, gross margin of —, operating margin of 75.0%, and return on invested capital (ROIC) of 85.0%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AnaptysBio Inc. (ANAB) reported $234.6M in annual revenue (up from $91.3M in FY2024, +157.0% YoY) and -$13.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($17.2M revenue, -$163.6M net income) through FY2025, ANAB scaled operating cash flow to $19.7M and free cash flow to $19.6M, backed by $364.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 60/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Free cash flow yield of 1.36% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $20.18 – $72.36 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 5.7x EV/EBITDA against 75.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies are mapped in the source data. Sector context is limited to Health Care and the Biotechnology: Pharmaceutical Preparations industry. Investors should watch for the litigation uncertainty flagged in the news feed, as well as the GSK label-expansion item, since both are referenced in the source as potential ripple sources, though their supply-chain linkages are not mapped.

  • Key Question #1: Can ANAB sustain or expand its 75.0% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $234.6M and free cash flow of $19.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ANAB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANAB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AnaptysBio Inc. (ANAB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANAB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANAB Bull vs. Bear Conversation Board — What's Your Call at $46.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANAB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANAB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $61.32 (+27.0%)
📌 Pinned Debate

An 85% ROIC and 75% operating margin, scoring 19 of 20 on the cash-engine pillar, show high-return operations relative to a $1.44B mark

An 85% ROIC and 75% operating margin, scoring 19 of 20 on the cash-engine pillar, show high-return operations relative to a $1.44B market cap.. When you look under the hood at ANAB, Fundamental Cash Engine is 19/20 with 0.0% gross margins and 85.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $72.36. My 12M target is $61.32.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $37.66 (-22.0%)
Spot @ $48.28

A -5.6% net margin, unresolved litigation uncertainty, and a weak 8 of 20 whale-flow reading leave the stock with limited institutional

Careful chasing ANAB at $48.28. A -5.6% net margin, unresolved litigation uncertainty, and a weak 8 of 20 whale-flow reading leave the stock with limited institutional conviction.. Gross margin is 0.0%, but operating margin is 75.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $37.66 on multiple compression.

LIVE TAPE